/ -- Abbott (NYSE: ABT) today announced results from its REFLECT real-world studies that show the use of FreeStyle Libre

/ -- 雅培（纽约证券交易所代码：ABT）今天宣布了其REFLECT真实世界研究的结果，结果显示FreeStyle Libre的使用

continuous glucose monitoring (CGM) technology is associated with a significant reduction in the risk of hospitalization for heart complications in people with diabetes. For the first time,

连续血糖监测（CGM）技术可显著降低糖尿病患者因心脏并发症住院的风险。这是首次发现，

show that CGM technology can help lessen the severity of cardiovascular complications – regardless of a prior history of low blood sugar events or heart disease-related hospitalizations – in individuals with Type 1 diabetes.

研究表明，CGM技术可以帮助减轻1型糖尿病患者的心血管并发症的严重程度——无论其是否有低血糖事件或与心脏病相关的住院史。

from the studies also show a similar reduction in heart-related hospitalizations for those with Type 2 diabetes on insulin using Libre biowearable technology.

研究还显示，使用Libre生物可穿戴技术的2型糖尿病患者因心脏相关问题住院的比例也出现了类似的下降。

Diabetes remains a serious chronic disease worldwide, affecting approximately 589 million people

糖尿病仍然是全球范围内的一种严重慢性疾病，影响着大约5.89亿人。

and often accompanied by cardiovascular complications.

并常伴有心血管并发症。

People with Type 1 and Type 2 diabetes are 2-4 times more likely than someone without diabetes to develop heart disease, a major cause of death for both groups.

1型和2型糖尿病患者患心脏病的可能性是普通人的2到4倍，心脏病是这两类人群的主要死亡原因之一。

While heart risks for Type 2 diabetes are well known, there's low awareness about heart complications in people with Type 1 diabetes. Adults with Type 1 diabetes who have had serious low blood sugar episodes are twice as likely to be hospitalized for heart-related issues.

虽然2型糖尿病的心脏风险广为人知，但人们对1型糖尿病患者心脏并发症的认识较低。患有严重低血糖发作的1型糖尿病成年人因心脏相关问题住院的可能性是常人的两倍。

For people with diabetes, the REFLECT findings suggest that the use of Libre technology could also potentially lead to lower healthcare costs due to the reduction in hospital admissions related to heart complications.

对于糖尿病患者，REFLECT 研究结果表明，由于与心脏并发症相关的住院次数减少，使用 Libre 技术也可能有助于降低医疗成本。

'These results are remarkable, as we see dual benefits from CGM technology in managing diabetes and its associated cardiovascular complications,' said one of the lead authors of the studies,

“这些结果非常显著，因为我们看到了CGM技术在管理糖尿病及其相关心血管并发症方面的双重益处，”这些研究的主要作者之一表示，

David Nathanson

大卫·纳森

, MD, PhD, Karolinska University Hospital in

，医学博士，哲学博士，卡罗林斯卡大学医院在

Sweden

瑞典

. 'CGMs empower people to proactively manage their diabetes and make informed health choices through real-time, constant feedback on their glucose levels. This data shows that using CGMs is linked with significantly reduced hospitalizations related to heart issues, which can have a significant impact on patients, their families and the healthcare system by easing medical, emotional and financial burdens.'.

“CGM使人们能够通过实时、持续的血糖水平反馈，主动管理糖尿病并做出明智的健康选择。数据显示，使用CGM与显著减少心脏问题相关的住院率有关，这可以减轻患者、他们的家庭以及医疗系统的医疗、情感和经济负担，带来重大影响。”

The findings also reveal that the risk of hospitalizations for cardiovascular disease was reduced by 80% among people with Type 1 diabetes with no prior history of cardiovascular disease when using the Libre biowearable technology compared to those who used a traditional blood glucose monitor. For individuals with a prior history of cardiovascular disease, the risk of hospitalizations was reduced by 49%..

研究结果还显示，与使用传统血糖监测仪的患者相比，对于之前没有心血管疾病史的1型糖尿病患者，使用Libre生物可穿戴技术可将因心血管疾病住院的风险降低80%。而对于有心血管疾病史的患者，住院风险则降低了49%。

'These data are transformative and show just how valuable FreeStyle Libre technology is for managing both diabetes and heart health, helping millions of people live healthy lives,' said

“这些数据具有变革性，展示了FreeStyle Libre技术在管理糖尿病和心脏健康方面的巨大价值，帮助数百万人过上健康生活，”

Mahmood Kazemi

马哈茂德·卡齐米

, M.D., chief medical officer for Abbott's diabetes care business. 'With its heart benefits, Libre makes it easier for people to take control of their health.'

医学博士，雅培糖尿病护理业务首席医疗官。“Libre 的心脏益处使人们更容易掌控自己的健康。”

The REFLECT research considered a range of cardiovascular-disease related conditions including non-fatal heart attack, non-fatal stroke, coronary artery disease, heart failure, atrial fibrillation and cardiovascular death – conditions commonly seen in people with diabetes.

REFLECT研究考虑了一系列与心血管疾病相关的状况，包括非致命性心脏病发作、非致命性中风、冠状动脉疾病、心力衰竭、心房颤动和心血管死亡——这些状况在糖尿病患者中很常见。

'I regularly treat people with diabetes who have problems with their blood vessels, resulting in heart attacks, strokes and amputations,' said

“我经常治疗那些因血管问题而导致心脏病发作、中风和截肢的糖尿病患者，”他说。

Ramzi Ajjan

拉米·阿贾恩

, M.D., professor of Metabolic Medicine at University of Leeds and Leeds Teaching Hospitals NHS Trust. 'These blood vessel problems, known collectively as cardiovascular disease, remain the main causes of ill health and death in people with diabetes. I am very excited to see data that show significant reduction in cardiovascular disease-related hospital admissions.

利兹大学和利兹教学医院NHS信托基金代谢医学教授M.D.表示：“这些血管问题统称为心血管疾病，仍然是糖尿病患者健康状况不佳和死亡的主要原因。看到数据显示与心血管疾病相关的住院人数显著减少，我感到非常兴奋。”

It's great to see the clear, positive impact of FreeStyle Libre technology on cardiovascular outcomes, making diabetes management more effective and improving the health of our patients.'.

看到FreeStyle Libre技术对心血管结果产生明确、积极的影响，真是令人鼓舞。它使糖尿病管理更加有效，并改善了我们患者的健康状况。

About REFLECT Studies:

关于REFLECT研究：

The REFLECT studies, funded by Abbott, were real-world retrospective studies conducted using data from the Swedish National Diabetes Register (NDR), one of the largest and most comprehensive diabetes registers in the world representing approximately 90% of all patients with diabetes in

REFLECT研究由雅培公司资助，是一项利用瑞典国家糖尿病登记处（NDR）数据进行的真实世界回顾性研究，该登记处是全球最大且最全面的糖尿病登记处之一，涵盖了大约90%的瑞典糖尿病患者。

, assessed: 1) the impact of intermittently scanned CGM versus blood glucose monitoring on HbA

评估了间歇扫描式CGM与血糖监测对HbA的影响：1）

levels and hospitalizations in adults with insulin-treated Type 2 diabetes; 2) the impact of intermittently scanned CGM versus blood glucose monitoring on hospitalization rates for metabolic and vascular complications and HbA

使用胰岛素治疗的2型糖尿病成人患者的水平和住院率；2）间歇性扫描CGM与血糖监测对代谢和血管并发症及HbA住院率的影响

levels for adults with Type 1 diabetes;

1型糖尿病成人患者的水平；

3) the risk of cardiovascular complications after severe hypoglycemia in adults with Type 1 diabetes, and the risk of post-severe hypoglycemia cardiovascular complications for intermittently scanned CGM users versus blood glucose monitoring users.

3）成人1型糖尿病患者在严重低血糖后出现心血管并发症的风险，以及间歇性扫描CGM用户与血糖监测用户在严重低血糖后心血管并发症风险的比较。

About FreeStyle Libre:

关于FreeStyle Libre：

Abbott continues to pioneer ground-breaking technology to support people living with diabetes. The company revolutionized diabetes care 10 years ago with its world-leading FreeStyle Libre continuous glucose monitoring portfolio, which today is used by more than 7 million people across over 60 countries..

雅培继续开创支持糖尿病患者生活的突破性技术。该公司十年前以其世界领先的FreeStyle Libre连续血糖监测系列产品彻底改变了糖尿病护理，如今该产品已在60多个国家被超过700万人使用。

People use Libre technology to see their glucose numbers in real-time, providing insights into how food, activity, or insulin impacts their glucose to help them make progress on their health goals. There is full or partial reimbursement for Libre systems in more than 40 countries.

人们使用Libre技术实时查看他们的血糖数值，提供有关食物、活动或胰岛素如何影响血糖的见解，帮助他们实现健康目标。在超过40个国家，Libre系统可以得到全额或部分报销。

About Abbott:

关于雅培：

Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Our 114,000 colleagues serve people in more than 160 countries..

Abbott是一家全球医疗保健领域的领导者，致力于帮助人们在生命的各个阶段更充实地生活。我们变革性的技术组合覆盖了整个医疗保健领域，在诊断、医疗器械、营养品和品牌仿制药方面拥有领先的企业和产品。我们的114,000名员工为超过160个国家的人们提供服务。